{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:29:11Z","timestamp":1791584951822,"version":"4.3.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antibody-drug conjugates (ADCs) offer selective delivery of potent cytotoxic payloads to tumour-associated antigens and are therefore attractive candidates for biomarker-informed treatment development. However, antigen heterogeneity, payload resistance, linker stability, and on-target\/off-tumour toxicities continue to complicate clinical translation. Several next-generation ADC programmes, including PSMA- and B7-H3-directed agents such as MEDI3726 and DS-7300, have reported early antitumour activity signals. At the same time, the global development landscape remains fragmented across targets, payload classes, endpoints, and sponsor types. This study therefore aimed to map the contemporary landscape of ADC clinical trials for prostatic neoplasms, clarify current development patterns, identify translational opportunities and gaps, and provide an integrated overview to support future clinical development.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1774353","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:32:06Z","timestamp":1778733126000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Global landscape analysis of antibody-drug conjugate clinical trials for prostatic neoplasms: current status, opportunities and challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Shuyu","family":"Ren","sequence":"first","affiliation":[{"name":"Rehabilitation Department, Second Affiliated Hospital, Zhejiang University School of Medicine, Linping Campus","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Pan","sequence":"additional","affiliation":[{"name":"Rehabilitation Department, Second Affiliated Hospital, Zhejiang University School of Medicine, Linping Campus","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"Rehabilitation Department, Second Affiliated Hospital, Zhejiang University School of Medicine, Linping Campus","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1544882","article-title":"The application of emerging immunotherapy in the treatment of prostate cancer: progress, dilemma and promise","volume":"16","author":"Che","year":"2025","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211053898","article-title":"PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going","volume":"13","author":"Giraudet","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4111\/icu.20250313","article-title":"Comparative effectiveness of androgen receptor pathway inhibitor treatment intensification for metastatic hormone-sensitive prostate cancer in real-world patients","volume":"66","author":"Lee","year":"2025","journal-title":"Investig Clin Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132216","article-title":"Apalutamide and stereotactic body radiotherapy in metastatic hormone-sensitive prostate cancer: multicenter real-world study","volume":"17","author":"Encarnaci\u00f3n","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.70389\/PJS.100082","article-title":"Transparency in the reporting of artificial intelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Premier J Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4528","article-title":"Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody-drug conjugate in patients with mCRPC after failure of abiraterone or enzalutamide","volume":"27","author":"de Bono","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.087","article-title":"DS-7300 (B7-H3 DXd-ADC) in patients with metastatic castration-resistant prostate cancer: a subgroup analysis of a phase 1\/2 multicenter study","volume":"40","author":"Patel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B9","volume-title":"MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobramitamab Duocarmazine in mCRPC Patients at ESMO Congress 2024","year":"2024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6732","article-title":"Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer","volume":"15","author":"Yamada","year":"2023","journal-title":"Sci Transl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162148","article-title":"Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models","volume":"133","author":"Agarwal","year":"2023","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","first-page":"23902","DOI":"10.1038\/s41598-025-06393-z","article-title":"Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA-negative cases","volume":"15","author":"Mulati","year":"2025","journal-title":"Sci Rep"},{"key":"B13","volume-title":"Clinical pharmacology considerations for antibody-drug conjugates: guidance for industry","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00371","article-title":"Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients","volume":"40","author":"Fourie Zirkelbach","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082160","article-title":"Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload","volume":"15","author":"Kondrashov","year":"2023","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00573-y","article-title":"Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer","volume":"26","author":"Mitchell","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7150\/thno.99516","article-title":"Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics","volume":"14","author":"Hong","year":"2024","journal-title":"Theranostics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774353\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:50:48Z","timestamp":1779695448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1774353\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2026.1774353"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1774353","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1774353"}}